IN8BIO

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clinical stage biopharmaceutical company IN8bio Inc (US:INAB) topped the Fintel Significant Insider Buying Activity screen this week with 11 insiders buying over the last 90 days.

11 Insiders Tip More Capital into IN8BIO and Broker HC Wainwright Initiates With Bullish $14 Target

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced the presentations it will be making at investor and scientific conferences in September 2022.

IN8bio to Present at September Investor and Scientific Conferences

NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that the underwriter of its previously announced underwritten public offering of common stock which closed on August 16, 2022 has partially exercised its option to purchase an additional 268,949 shares at the public offering price of $1.90 per share, resulting in additional gross proceeds of approximately $0.5 million. After giving effect to the partial exercise of the option to purchase additional shares, the total number of shares sold by IN8bio in the public offering increased to 5,663,686 shares and gross proceeds increased to approximately $10.75 million.

IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering

NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the closing of its previously announced underwritten public offering of 5,394,737 shares of its common stock at a public offering price of $1.90 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $10.25 million.

IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock

NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced financial results and operational highlights for the quarter ended June 30, 2022. In addition, the Company provided an overview of recent corporate developments.

IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the pricing of an underwritten public offering of 5,394,737 shares of its common stock at a public offering price of $1.90 per share. IN8bio also granted the underwriter a 30-day option to purchase up to an additional 657,894 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about August 16, 2022, subject to the satisfaction of customary closing conditions.

IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock

NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, provided a clinical update from the ongoing Phase 1 trial of INB-100. This program is an allogeneic, or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT). William Ho, Chief Executive Officer of IN8bio, will be discussing these results at the 3 rd Annual Gamma-Delta T Therapies Summit, being held July 26-28, in Boston.

IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients

NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on advancing innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the issuance of an additional European patent covering the composition of matter for IN8bio's Drug Resistant Immunotherapy (DRI) platform. The patent broadens the Company's intellectual property coverage of genetically engineered innate immune cells beyond gamma-delta T cells to include NK cells. Like gamma-delta T cells, NK cells respond directly to cellular stress and have shown promise in cellular therapy clinical trials. This newly issued patent bolsters the broad global patent portfolio that IN8bio has developed to support its core technology of chemotherapy resistance to enhance the efficacy of cellular therapies against solid tumor cancers.

Newly Issued European Patent Broadens IN8bio's Drug Resistant Immunotherapy (DRI) Platform

NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced an appointment to its executive team to lead the Company's business development efforts. Kenneth R. LaMontagne, Ph.D., joins the company as Senior Vice President, Business Development, to advance the company's partnership strategy and execute collaborative transactions to promote growth.

IN8bio Appoints Kenneth R. LaMontagne, Ph.D.

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced July conference presentations:

IN8bio to Present at July Investor and Scientific Conferences

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, announced that William Ho, CEO will be presenting today at 1:30pm EDT at the Jefferies Global Healthcare Conference. A live audio webcast of the presentation will be available and via the Company's Investor Relations page following the event. Additional June conference presentations include:

IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced updated safety and durability data from the Phase 1 clinical trial of INB-200 in patients with newly diagnosed glioblastoma multiforme (GBM). The data were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. INB-200 is a genetically engineered gamma-delta T cell product candidate that is designed to be chemotherapy resistant as part of the company's core Drug Resistant Immunotherapy (DRI) platform.

IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022

NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced data emerging from the Company's recently unveiled iPSC-based gamma-delta T cell platform. iPSCs represent a significant step toward next generation approaches of cellular manufacturing for true allogeneic ‘off-the-shelf' innate cell therapies, and further broaden the Company's capabilities around the expansion and genetic engineering of gamma-delta T cells.

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced financial results and operational highlights for the quarter ended March 31, 2022. In addition, the Company provided an overview of recent corporate developments.

IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced the Company's new induced pluripotent stem cell (iPSC) based gamma-delta T cell platform. We have demonstrated that we are one of the few companies than can differentiate iPSC-derived immune cells and the first to produce both iPSC-derived Vdelta1 (Vd1+) and Vdelta2 (Vd2+) gamma-delta T cell subtypes. This platform represents a new phase in IN8bio's growth as it advances technology that is designed to enable scaled manufacturing of ‘off-the-shelf' cellular therapies.

IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting

NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced May conference presentations:

IN8bio to Present at May Investor and Scientific Conferences

NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the additions to its clinical and regulatory team as the Company seeks to expand its clinical pipeline with at least one new company sponsored investigational new drug application (IND) this year. IN8bio has appointed Urvashi Patel, Ph.D., as Vice President, Regulatory Affairs and Stacey Bilinski, as Vice President, Clinical Operations. They bring deep clinical and regulatory experience to the IN8bio team, from early to late-stage development across the biotechnology and pharmaceutical industries with over 45 years of combined experience.

IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments

NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced April conference presentations:

IN8bio to Present at April Investor and Scientific Conferences

NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, presented a clinical update from the ongoing Phase 1 trial of INB-100. This program is an allogeneic, or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with leukemia undergoing haploidentical hematopoietic stem cell transplant (HSCT). Two of the INB-100 patients treated have been in remission for nearly two years, and the third patient is in continuing remission at nine months post-treatment.

IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced financial results and operational highlights for the fourth quarter and full-year ending December 31, 2021. In addition, the Company provided an overview of recent corporate developments.

IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company, today announced March conference presentations:

IN8bio to present at March Investor and Scientific Conferences

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company today announced that Company executives will be presenting at the following events:

IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that William Ho, Chief Executive Officer and co-founder of IN8bio, will present at four upcoming virtual investor conferences in January.

IN8bio to Present at Upcoming January Investor Conferences

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, provided an update today from the ongoing Phase 1 clinical trial of INB-200, an autologous DeltEx drug resistant immunotherapy (DRI). DeltEx DRI consists of gamma-delta T cells that have been genetically engineered to be chemotherapy resistant, allowing them to be administered concurrently with alkylating chemotherapeutic agents, including temozolomide (TMZ). This clinical trial, conducted in patients newly diagnosed with glioblastoma multiforme (GBM), is the first and most clinically advanced trial to use genetically modified gamma-delta T cells and includes a multi-dose escalation regimen.

IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

IN8bio Inc (NASDAQ: INAB) has provided an update on the Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapy for leukemia patients undergoing haploidentical hematopoietic stem cell transplant (HSCT).  The three patients with relapsed acute myeloid leukemia (AML) treated to date demonstrate that allogeneic gamma-delta T cell therapy has a manageable toxicity profile with the potential for durable responses in high-risk patients.

News for IN8BIO Stock (INAB)